Skip to content

Study · Non-randomized trial · n = 277 · 2006

4 results

[Results of the multicenter prospective study of cerebrolysin safety and efficacy in acute stroke].

Skwortsova VI, Stakhovskaia LV, Shamalov NA, Kerbikov OB

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2006Cited by 4 (Europe PMC)

PMID18196634 (opens in a new tab)PepBankPUB-18196634
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with ischemic stroke, Cerebrolysin accelerated NIHSS improvement on days 10 and 28 versus basic treatment only (p<0,05).

    In plain wordsIn patients with ischemic stroke, Cerebrolysin accelerated neurological improvement compared with basic treatment only.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNIHSS improvement on days 10 and 28
    Study

    n = 277

    Comparator
    Basic treatment only
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml daily · 10 daysAs given in this study (human).

    Measurements

    P value
    < 0.05
    NIHSS score improvement, cerebrolysin versus basic treatment only, days 10 and 28

    Source sentences

    Summary
    A quantitative analysis of the dynamics of neurological deficit revealed the accelerated improvement by NIHSS score, modified Rankin score and Barthel index in the cerebrolysin group on days 10 and 28 (p<0,05).
    3 context sentences
    Summary · context
    The multicenter prospective study of cerebrolysin safety and efficacy included 277 patients with ischemic stroke aged 55-85 years, who received therapy within 12 h from the disease development.
    Summary · context
    Cerebrolysin was used in dosage 10 ml daily along with concomitant standard basic treatment during 10 days after stroke onset in 138 patients.
    Summary · context
    A control group comprised 139 patients who received basic treatment only.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with ischemic stroke, Cerebrolysin accelerated modified Rankin improvement on days 10 and 28 versus basic treatment only (p<0,05).

    In plain wordsIn patients with ischemic stroke, Cerebrolysin accelerated modified Rankin improvement compared with basic treatment only.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseModified Rankin improvement on days 10 and 28
    Study

    n = 277

    Comparator
    Basic treatment only
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml daily · 10 daysAs given in this study (human).

    Measurements

    P value
    < 0.05
    modified Rankin score improvement, cerebrolysin versus basic treatment only, days 10 and 28

    Source sentences

    Summary
    A quantitative analysis of the dynamics of neurological deficit revealed the accelerated improvement by NIHSS score, modified Rankin score and Barthel index in the cerebrolysin group on days 10 and 28 (p<0,05).
    3 context sentences
    Summary · context
    The multicenter prospective study of cerebrolysin safety and efficacy included 277 patients with ischemic stroke aged 55-85 years, who received therapy within 12 h from the disease development.
    Summary · context
    Cerebrolysin was used in dosage 10 ml daily along with concomitant standard basic treatment during 10 days after stroke onset in 138 patients.
    Summary · context
    A control group comprised 139 patients who received basic treatment only.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with ischemic stroke, Cerebrolysin accelerated Barthel index improvement on days 10 and 28 versus basic treatment only (p<0,05).

    In plain wordsIn patients with ischemic stroke, Cerebrolysin accelerated daily-function improvement compared with basic treatment only.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBarthel index improvement on days 10 and 28
    Study

    n = 277

    Comparator
    Basic treatment only
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml daily · 10 daysAs given in this study (human).

    Measurements

    P value
    < 0.05
    Barthel index improvement, cerebrolysin versus basic treatment only, days 10 and 28

    Source sentences

    Summary
    A quantitative analysis of the dynamics of neurological deficit revealed the accelerated improvement by NIHSS score, modified Rankin score and Barthel index in the cerebrolysin group on days 10 and 28 (p<0,05).
    3 context sentences
    Summary · context
    The multicenter prospective study of cerebrolysin safety and efficacy included 277 patients with ischemic stroke aged 55-85 years, who received therapy within 12 h from the disease development.
    Summary · context
    Cerebrolysin was used in dosage 10 ml daily along with concomitant standard basic treatment during 10 days after stroke onset in 138 patients.
    Summary · context
    A control group comprised 139 patients who received basic treatment only.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with ischemic stroke, Cerebrolysin within the first 3h improved NIHSS more on day 28 than initiation within 6-12h (p<0,05).

    In plain wordsIn patients with ischemic stroke, Cerebrolysin within 3h improved neurological scores more than initiation within 6-12h.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNIHSS improvement by treatment initiation time
    Study

    n: not reported in source

    Comparator
    Cerebrolysin initiated within 6-12h
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml daily · 10 daysAs given in this study (human).

    Measurements

    P value
    < 0.05
    NIHSS score improvement on day 28, cerebrolysin within first 3h versus within 6-12h after stroke onset

    Source sentences

    Summary
    The significant improvement of NIHSS score was observed on day 28 (p<0,05) in patients treated with cerebrolysin within the first 3h after stroke onset comparing to those treated within 6-12h.
    3 context sentences
    Summary · context
    The multicenter prospective study of cerebrolysin safety and efficacy included 277 patients with ischemic stroke aged 55-85 years, who received therapy within 12 h from the disease development.
    Summary · context
    Cerebrolysin was used in dosage 10 ml daily along with concomitant standard basic treatment during 10 days after stroke onset in 138 patients.
    Summary · context
    A control group comprised 139 patients who received basic treatment only.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.